Related Experiment Video
Updated: Feb 3, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis
Qiuxiang Xiao1, Shaochun Yang2, Guanfu Ding2
1Department of Pathology, The first Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, China.
Abstract:
Glioblastoma is one of the most common primary brain tumors in adults. The current treatment strategies failed to achieve satisfactory outcomes. Anti-vascular endothelial growth factor (anti-VEGF) agents have been proposed to enhance the survival and quality of life in these patients. To investigate this, different databases were searched in addition to hand searching. Relevant studies were screened and only ten randomized controlled trials (RCTs) met the eligibility criteria; six of them were considered for meta-analysis. Eligible RCTs were assessed regarding risk of bias using the Cochrane tool. Relevant data were extracted and meta-analysis was conducted using the random effects model analysis on RevMan software. One thousand seventy-eight patients in the anti-VEGF group and 946 patients in the control group were available for analysis. No statistically significant improvement in the overall survival (OS) was detected for anti-VEGF (OR 0.87, 95% CI 0.7-1.09, p = 0.23) or bevacizumab subgroup (OR 0.84, 95% CI 0.65-1.08, p = 0.17) compared to standard therapy alone. However, the progression-free survival (PFS) showed a significant improvement with both anti-VEGF (OR 0.76, 95% CI 0.65-0.89, p = 0.0007) and bevacizumab subgroup (OR 0.75, 95% CI 0.65-0.87, p = 0.0001). In conclusion, anti-VEGF agents can improve the PFS but not OS in glioblastoma patients. The current evidence is not satisfactory to declare a new therapeutic line. Further RCTs with sharply determined outcomes and assessment methods are required.
Insights
Anti-vascular endothelial growth factor (anti-VEGF) agents improved progression-free survival (PFS) in glioblastoma patients but did not significantly impact overall survival (OS). Further research is needed to establish their therapeutic role.
Area of Science:
- Neuro-oncology
- Clinical trial analysis
- Cancer therapeutics
Background:
- Glioblastoma is a common adult primary brain tumor with limited treatment options.
- Current therapies for glioblastoma often yield unsatisfactory outcomes.
- Anti-vascular endothelial growth factor (anti-VEGF) agents are being explored to improve patient survival and quality of life.
Purpose of the Study:
- To evaluate the efficacy of anti-VEGF agents in glioblastoma treatment.
- To determine the impact of anti-VEGF agents on overall survival (OS) and progression-free survival (PFS).
Main Methods:
- A systematic search of multiple databases and hand searching was conducted.
- Ten randomized controlled trials (RCTs) met eligibility criteria; six were included in a meta-analysis.
- Data were extracted, and a random-effects model meta-analysis was performed using RevMan software.
Main Results:
- Meta-analysis included 1078 patients in the anti-VEGF group and 946 in the control group.
- No significant improvement in overall survival (OS) was observed for anti-VEGF agents (OR 0.87, p=0.23) or bevacizumab (OR 0.84, p=0.17).
- Significant improvement in progression-free survival (PFS) was noted for anti-VEGF agents (OR 0.76, p=0.0007) and bevacizumab (OR 0.75, p=0.0001).
Conclusions:
- Anti-VEGF agents demonstrate efficacy in improving PFS for glioblastoma patients.
- These agents do not significantly improve OS in glioblastoma.
- Current evidence is insufficient to establish anti-VEGF agents as a standard therapy; further high-quality RCTs are required.
More Related Videos
05:56Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
Published on: January 22, 2020
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview